[1] 张明娟,刘佳,向晓星,等.TACE联合索拉非尼治疗晚期肝癌的Meta分析.中华肿瘤防治杂志,2015,22:148-154+160.
[2] 郭启勇,温锋.肝细胞癌介入治疗的现状与展望.临床肝胆病杂志,2013,29:721-725.
[3] 叶胜龙.肝癌的局部区域治疗.临床肝胆病杂志,2013,29:28-31.
[4] Leonardi MC, Zampino MG, Luca F, et al. Pre-operative radiochemotherapy with raltitrexed for resectable localy advanced rectal cancer: aphase Ⅱ study. Anticancer Res,2006,26:2419-2423.
[5] Wilson KS, Malfair Taylor SC. Raltitrexed:optimism and reality. Expert Opin Drug Metab Toxicol,2009,5:1447-1454.
[6] Gravalos C, Salut A, Garcia-Giron C, et al. A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer. Clin Transl Oncol,2012,14:606-612.
[7] 郝明春,殷学治,王辉,等.抗癌药雷替曲塞的合成.中国药物化学杂志,2007:368-371
[8] Zhao C, Fan L, Qi F, et al. Raltitrexed plus oxaliplatin-based transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. Anticancer Drugs, 2016, 27:689-694.
[9] Khouri C, Guiu B, Cercueil JP, et al. Raltitrexed and oxaliplatin hepatic arterial infusion for advanced colorectal cancer: a retrospective study. Anticancer Drugs,2010,21:656-661.
[10] 贺红杰,宋磊,赵丹懿,等.雷替曲塞联合奥沙利铂经TACE治疗不可切除肝癌患者的疗效评价.介入放射学杂志,2016,25:40-43. |
